Get the Stockscreener App
0.5073
9.57%
-0.0537
After Hours:
.51
0.0027
+0.53%
Kala Bio Inc stock is traded at $0.5073, with a volume of 250.77K.
It is down -9.57% in the last 24 hours and down -31.72% over the past month.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.561
Open:
$0.545
24h Volume:
250.77K
Relative Volume:
1.92
Market Cap:
$9.81M
Revenue:
$420.00K
Net Income/Loss:
$-19.65M
P/E Ratio:
-0.00367
EPS:
-138.243
Net Cash Flow:
$-26.08M
1W Performance:
-26.49%
1M Performance:
-31.72%
6M Performance:
-97.06%
1Y Performance:
-99.93%
1-Day Range:
$0.5006
$0.5569
1-Week Range:
$0.5006
$0.76
52-Week Range:
$0.5006
$1,030.00
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.5073 | 16.25M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO (KALA) Climbs 4.4% to $0.73 as Bulls Target $0.77 ResistanceRevenue Weighted - Vinanet
KALA Q2'26 Earnings: EPS estimate is (6.00) USD - TradingView
KALA BIO Inc. (KALA) Gains 3.59% to $0.76 — Approaches Key Resistance at $0.80Systematic Flow - vinanet.vn
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Cash Flow - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KALA Q4 2025 Earnings: Significant Beat on EPS Despite No Reported RevenueRevenue Inflection Point - vinanet.vn
TradingKey - TradingKey
KALA BIO Inc (KALA) Balance Sheet - TradingKey
KALA|KALA BIO Inc|Price:0.740|Chg%:-0.003 - TradingKey
KALA|KALA BIO Inc|Price:0.671|Chg%:+0.036 - TradingKey
KALA BIO, Inc. Revenue Breakdown – NASDAQ:KALA - TradingView
KALA|KALA BIO Inc|Price:0.634|Chg%:+0.024 - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
KALA Q4 2025 Earnings: EPS Beat Masks Revenue Woes as Stock Slides 17%Financial Data - vinanet.vn
Kala Bio Files ATM Offering Of Up To $250 Million In Common StockSEC Filing - TradingView
Frontier tech research, news & data - MLQ.ai
KALA BIO Shares Plunge Over 7% as Stock Nears Critical Support LevelGamma Flip Level - vinanet.vn
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Form 13D/A KALA BIO For: 2 July By Investing.com - Investing.com Nigeria
David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
Price to earnings forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA BIO Inc. (KALA) Holds Near Support After Slight Decline: Key Levels in FocusVanna Flow - dars.gov.et
[EFFECT] KALA BIO, Inc. SEC Filing - Stock Titan
Enterprise value to EBIT forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to EBITDA forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Price to book forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to revenue forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA Q4 2025 Earnings: EPS Beats Estimates, Stock Surges 26.9%Slow Growth Warning - dars.gov.et
KALA BIO StockLong-term eye-disease strategy in focus - AD HOC NEWS
KALA BIO Inc (KALA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):